— Viking Therapeutics Inc. (NASDAQ: VKTX) reported Q3 2019 loss of $0.08 per share, vs. a loss of $0.13 expected. — Net loss amounted to $5.7 million compared to $6.6 million last year. — R&D expenses were $5.3 million compared to $5.7 million in the year-ago quarter. — General and administrative expenses were $2.2 million […]
“— Viking Therapeutics Inc. (NASDAQ: VKTX) reported Q3 2019 loss of $0.08 per share, vs. a loss of $0.13 expected. — Net loss amounted to $5.7 million compared to $6.6 million last year. — R&D expenses were $5.3 million compared to $5.7 million in the year-ago quarter. — General and administrative expenses were $2.2 million […]
· November 5, 2019
— Viking Therapeutics Inc. (NASDAQ: VKTX) reported Q3 2019 loss of $0.08 per share, vs. a loss of $0.13 expected.
— Net loss amounted to $5.7 million compared to $6.6 million last year.
— R&D expenses were $5.3 million compared to $5.7 million in the year-ago quarter.
— General and administrative expenses were $2.2 million compared to $1.7 million last year.
— At quarter-end, the company had cash, cash equivalents and short-term investments of $288.1 million.
— VKTX shares gained 0.15% following the announcement.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
